Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vectura Group and Sosei Group have reported that Novartis has initiated a Phase II efficacy study of QVA149 for the treatment of chronic obstructive pulmonary disease.
Subscribe to our email newsletter
This second Phase II study is a randomized, double-blind, placebo-controlled, multi-centre trial to determine the effect of QVA149 on lung function in patients with moderate to severe COPD.
QVA149 is a combination of NVA237, a once-daily long-acting muscarinic antagonist (LAMA) and indacaterol, a once-daily long-acting beta-2 agonist (LABA).
NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to $375 million in milestones as well as royalties on product sales. Indacaterol was discovered by Novartis and is currently in Phase III trials for COPD.